Locations:
Search
Observational findings over 5+ years of follow-up argue for caution in this population
FDA-designated breakthrough device offers first treatment option for severe TR and right HF
Essentials of the NIH study and how it compares with REPAIR MR
Also, earlier surgery likely benefits patients with severe functional TR
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Concomitant repair is a trade-off if tricuspid regurgitation is less than severe
Series finds short-term outcomes excellent, but BAV may be less durable
Companion study shows apparent benefit from surgery in both primary and secondary TR
Definitions give new weight to secondary and composite endpoints, quality-of-life metrics
Findings reveal lower survival, fewer interventions relative to primary MR
JACC State-of-the-Art Review features care algorithm and more
Advertisement
Advertisement